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Purpose. Optimized biocompatibility is a major requirement for alloplastic materials currently applied for stress urinary
incontinence (SUI) and pelvic organ prolapse (POP) repair. In the preliminary studies the mesh modification by coating with
autologous plasma resulted in the increased adherence score in vitro and improved biocompatibility in an animal model. The
first use of plasma coated meshes in human is presented. Materials and Methods. Between 04/2013 and 05/2014, 20 patients with
the indication for SUI and POP repair were selected in a single institution. The applied meshes were modified by autologous
plasma coating prior to implantation. A retrospective chart review for peri- and early postoperative complications was performed.
Functional outcome and QoL were evaluated pre- and postoperatively. Results. The functional outcome and QoL improved
significantly in all groups. Two reoperations (Grade IIIB) with the release of TVT-mesh in anesthesia due to the obstruction were
needed. No other severe complications were registered. Conclusion. For the first time we applied a mesh modification in a human
setting according to IDEAL criteria of surgical innovations. The procedure of mesh coating with autologous plasma is safe and
a prospective randomized trial proving a positive effect of plasma coating on the biocompatibility and morbidity outcome with
long-term registry is planned.
1. Introduction
Currently the approval of medical devices as surgical meshes
is regulated by American Food and Drug Administration
(FDA) and European guidelines according to risk classifica-
tion. Clinical trials and postmarket followup were not requi-
red for the commercial approval. In a Public Health Notific-
ation (PHN), from 2008, the FDA reported more than 1000
unexpected and severe adverse events, associated with tran-
svaginal placement of surgical mesh to treat POP and SUI. In
2011, a second FDA warning has been amended, proposing
an upgrading in risk classifications for meshes, which would
allow the request of premarket approval and postmarket
surveillance studies [1].
Meshes or grafts potentially add to the complication pro-
file the aspects of trauma of insertion, foreign body reaction
to the implant in terms of inflammation, infection and/or
rejection, and the stability of the prosthesis over time [2].
Polypropylene meshes (Type 1, Amid-classification) are usu-
ally used for vaginal repair of POP and SUI [3]. The rate of
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Table 1: Material and biomechanic characteristics of selected meshes [7, 9, 10, 14, 28–31].
Mesh Material Biomechanic characteristics Adhesion score(Melman)
Adhesion score after
coating with plasma
(Melman)
Seratim PA, Serag
Wiessner
Monofilament
polypropylene,
polyglycol acid,
and caprolacton
Partly absorbable (90–120 days)
Pore size: 5800 𝜇m (11mm2)
Weight: 15 g/m2 (after resorption)
Thickness: 0.5mm
Tear resistance (𝐹max): 80N
2.5 Pending
Vitamesh,
ProxyBiomedical
Monofilament
polypropylene
Nonabsorbable
Weight: 35 g/m2
Pore size: 2410 𝜇m
Thickness: 0.25mm
Tear resistance (𝐹max): 33.7N
1.6 1.9
UltraPro, Ethicon
Monofilament
polypropylene
reinforced with
poliglecaprone
fibers (Monocryl)
Partly absorbable (90–120 days)
Pore size: 3000–4000 𝜇m
Weight: 28 g/m2 (after resorption)
Thickness 0.5mm
Tear resistance (𝐹max): 69N
1.4 1.6
TVT, Johnson and
Johnson
Monofilament
polypropylene
Nonabsorbable
Pore size: <1000𝜇m
Weight: 105–110 g/m2
Thickness: 0.7mm
Tear resistance (𝐹max): about 10N
1 1.6
mesh-related complications after transvaginal mesh applica-
tion for POP is about 15–25% and especially mesh erosion
up to 10% for these indications [4, 5]. Most common com-
plications after MUS (midurethral sling) are obstruction, de
novo urge, chronic pain, dyspareunia, and mesh erosion [6].
The complications are attributed to a considerable extent to
the wrong indication and faulty surgical techniques; material
properties are the other reasons. The choice of the optimal
mesh for a particular indicationwith the highest functionality
(hold shape) as well as minimized side effects remains
difficult. Mesh material (type of polymer, pore size, and
material weight, etc.) and its biocompatibility were detected
to be crucial parameters [7, 8]. A biocompatibility is
described by the foreign body reaction (FBR) at the host-
tissue/biomaterial interface. The dynamic of the FBR is given
by the inflammatory host response depending on the bio-
material composition (Table 1) [7, 9, 10]. The current under-
standing about an optimized surgical mesh describes a
material that permits the transmigration and localisation of
beneficial host cells and if directly exposed to visceral
organs, vessels, or nerves it strongly inhibits the adherence of
the respective organs in order to avoid erosion, foreign body
provoked pain, and so forth. Inert (Titan), (partly) absor-
bable, light-weight materials are currently under develop-
ment. Sophisticated methods, like preoperative coating of
mesheswith a protective layer on the visceral side of themesh,
have been frequently investigated,mostly in vivo [11, 12].They
seem to present a potential approach to reduce foreign body
reaction and improve biocompatibility and therefore have
been introduced in mesh applying surgery.
In a considerably narrow time frame, reacting to the
first and second FDA warnings, our international scientific
collaboration group has recently developed and concluded
preliminary studies in order to investigate and improve
biocompatibility of surgical meshes. Our entire innovative
approach has been conducted following the five-step IDEAL
model for surgical innovations (Innovation, Development,
Exploration, Assessment, and Long-term study) with the aim
ofmaintaining it comparable and reproducible at every single
step of development [13]. A validated in vitro test system to
compare biocompatibility features of different meshes has
been developed (Idea, first stage) [9]. This test system was
subsequently expanded, to show that mesh modification by
autologous plasma coating results in higher biocompatibility
and adherence score in vitro [9, 10].The predictability of these
approaches, biocompatibility evaluation, and improvement
by plasma coating could then be validated and confirmed in a
two-year large animal study (Development, second stage) [14].
In particular, an early inflammation reaction seems to be
influenced by the coating procedure [15]. Herewith we
present a consecutive study on the first clinical assessment of
meshes modified by autologous plasma coating in human
(Exploration, third stage).
2. Materials and Methods
Patients (age > 18 y) with surgical indication for SUI (Stamey
grade ≥ I) and POP (POP-Q Grades I–III and anterior and
apical prolapse) repair with mesh were selected after the
informed consent. In case of POP and SUI a concomitant
Burch colposuspension was performed. All patients expe-
rienced an unsuccessful treatment with medicaments and
physiotherapy prior to operation. The male patients pre-
sented amoderate SUI (grade I-II, 2–6 pads/day) after radical
prostatectomy. Urodynamics and urethrocystoscopy were
performed prior to the operation and a partial defect of the
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Figure 1: The technique of mesh coating with autologous plasma. (a) Vein puncture, 20–40mL blood is obtained in EDTA-tube before
anesthesia. (b) Centrifugation of blood sample in the operation room. (c) Plasma is abstracted and incubated with the mesh in a bowl. (d)
The coated mesh is implanted. The rest of plasma is spilled over the implantation site.
(a) (b)
Figure 2: TVT-procedure. (a) Coating of TVT-mesh with autologous plasma. (b) Insertion of retropubic midurethral sling.
external sphincter was revealed. According to the IDEAL
model a sophisticated, well-defined selection of patients was
performed. The exclusion criteria were previous mesh
implantation at the operation site, infection, chemo- or
immunological therapy during the last three months, psychi-
atric illness or inability to answer the questionnaire, and preg-
nancy. Different mesh materials were used (TVT, Seratim,
Ultrapro, and Vitamesh) (Table 1). 20–40mL blood sample
was obtained in the EDTA-tube (ethylenediaminetetraacetic
acid) from the respective patient by vein puncture before the
induction of anesthesia.The blood collection and centrifuga-
tion of blood sample (4000 rpm for 10min) was performed
in the operation room in order to prevent the contamination.
The clear supernatant (plasma) after centrifugation of the
precipitation was removed with sterile syringe. Before the
implantation the meshes were incubated for 30min with
10–20mL (depending on the size of the mesh) autologous
plasma in a bowl (Figures 1 and 2).The surgical techniquewas
not altered by the application of this technology (Figure 2).
The patients were examined pre- and postoperatively and
interviewed before the operation and on telephone 6–8weeks
after the operation. For high grade POP (grade ≥ III) a peri-
operative ureteral stenting for about two weeks was per-
formed. Ultrasound controls for residual urine volume and
hydronephrosis were done after catheter removal on the
third postoperative day. In cases of obstruction due to MUS
(midurethral sling) a prolonged catheterisation was needed.
If the voiding dysfunction persisted (residual volume >
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Table 2: Patient characteristics.
Procedure TVT TOT Anterior vaginal mesh Sacrocolpopexy
Number of patients (gender) 7 (female) 4 (male) 1 (female) 8 (female)
Age, mean (yr) 67 (57–85) 71 (70–72) 58 64 (45–75)
Operation time, mean (min) 36 (31–49) 46 (42–55) 51 57 (43–71)
Followup, median (mos) 3 (2–4) 4 (2–7) 3 3 (1–4)
Concomittant procedures 1 × SSF No 1 × SSF 8 × Burch, 1 × Rectopexy
SSF: sacrospinous fixation.
Table 3: Peri- and early postoperative complications.
Procedure TVT TOT Anterior vaginal mesh Sacrocolpopexy Total IUGA/ICS-classification
Number of patients (gender) 7 (female) 4 (male) 1 (female) 8 (female) 20
Complications, number (%)
Clavien-Dindo Grade I
Prolonged pain 0 1 (25%) 0 1 (12.5%) 2 (10%) 6Be/S4
Hematoma 1 (14%) 1 (25%) 0 0 2 (10%) 7A/S3/S4
Urge de novo 3 (43%) 0 0 0 3 (15%) 4B/site?
Obstruction (prolonged cath.) 1 (14%) 0 1 (100%) 0 2 (10%) 4B/site?
Grade II
UTI 2 (28%) 0 0 2 (25%) 4 (25%) 4B/site?
Grade III
Obstruction (reoperation) 2 (28%) 0 0 0 2 (10%) 4B/S1
Bladder/bowel injury 0 0 0 0 0 4A/S3, 5A/B/S5
Fistula 0 0 0 0 0 4/5B/S1 or S2
Mesh exposure 0 0 0 0 0 2B or 3B/S1 or S2
QoL improved 6 (86%) 2 (50%) 1 (100%) 7 (87.5%) 16 (80%)
200mL) an endoscopic evaluation with cystoscopic release
of the sling was performed. The patient charts were searched
for perioperative and early postoperative complications. The
safety of our technology for the patient was validated by the
Clavien-Dindo classification of surgical complications and
ICS/IUGA classification [2, 16]. The quality of life (QoL) was
assessed by P-QOL and ICIQ-SF 2004 questionnaires [17]. In
cases of explantation the immunhistochemistry analyses of
the mesh are planned [7, 14].
3. Legal Requirements
The application of autologous blood plasma coating was
performed according to the German Pharmaceutical Law
(AMG), theMedical Product Act (MPG) and the Transfusion
Act. The permission for this new experimental method was
provided by local government. According to the statement of
the local government, the preparation of autologous blood
plasma and the modification of the mesh by the coating
procedure are subject to paragraph 13, 2 b, of theAMGand no
permission according to paragraph 13, 1, of the AMG is
necessary.
The patients were carefully educated on the experimental
technique and possible complications. Because of the retro-
spective data evaluation no ethical approval was necessary.
4. Results
Between 04/2013 and 05/2014, 20 patients (16 females and 4
males) with the indication for SUI and POP repair with mesh
graft were selected for surgery in a single institution. The
patient characteristics are described in Table 2. The mean
age was 67 years (45–85) and the mean followup was 3
months [1–7]. 11 patients were treated for SUI (grades II-III,
Stamey score) and 9 patients were treated for POP (POP-
Q grades I–III, anterior and apical prolapse). In 50% of
patients concomitant operations (Burch colposuspension,
sacrospinous fixation, and rectopexy) were performed. No
intraoperative problems or complications (transfusion reac-
tion, etc.) associated with mesh coating with autologous
plasma were observed. Two reoperations (10%, Clavien-
Dindo Grade IIIB) with the cystoscopic release of TVT-mesh
in anesthesia due to the obstruction were needed. No other
severe complications (mesh exposure, bladder or bowel
injury, and fistula) were registered. Prolonged perineal para-
esthesia and hematoma were observed in 2 cases after TOT
(50%) (Table 3). An 85-year female with extended usage of
analgesics and antidepressant agents presented a prolonged
voiding dysfunction after TVT. Prolonged catheterization
and the cystoscopic release were not successful. A suprapubic
tube was inserted, the antidepressants were reduced, and the
medication with Ubretid was started. A 76-year female pre-
sented persisting SUI after the anterior POP repair (grade III)
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with sacrocolpopexy and consecutive TVT (plasma-coated).
The postoperative examination revealed a persisting Grade
II-cystocele. A reoperation with colporrhaphy and plasma-
coated vaginal mesh application is planned. Two of four male
patients after TOT procedure complained about persisting
SUI (>1 pad/day); in these cases an artificial urinary sphincter
was planned. The functional outcome and QoL improved
overall in all groups during the followup. No mesh resections
or explantations were necessary up-to-date.
5. Discussion
The preliminary work on the principles of plasma coating
were described in in vitro and animal studies previously [9, 10,
14, 15]. Our study illustrates the first clinical usage of themesh
modification by autologous plasma for POP and SUI repair.
The observed early perioperative complications correspond
to the data of current meta-analyses and studies [4, 5, 18].
Voiding dysfunction, UTI, recurrent SUI, and paraesthesia
were described previously and are associated mostly with the
surgical technique and not to the mesh modification. The
procedure is safe and offers good functional results. The only
Grade III (Clavien-Dindo) complication in the TVT-group
was the obstruction with the need of reoperation. This
complication is due to the operation technique and has no
relation to the coating procedure. The technique of plasma
coating is an easy-to-do and timely procedure. No addi-
tional complications or intraoperative problems due to this
technique were observed. The complications were graduated
according to Clavien-Dindo and ICS (International Conti-
nence Society)/IUGA (International Urogynecologic Associ-
ation) classification. The ICS/IUGA classification is based on
the information on the category, time, and location of compli-
cations. We had problems to make a precise classification for
some complications due to inconsistent definitions (Table 3).
Because of high complexity and low concordance in different
trials ICS/IUGA-classification is currently rarely used [4, 19].
However, we consider the classification to be valuable for the
report of long-term data in registries.
The current studies show the importance of acute inflam-
matory and immune responses for the integration of mesh
into the surrounding tissue [9, 10, 15]. Foreign body reaction
(FBR) often causes a fibrotic rebuilding of implants and the
loss of functions (loss of flexibility, etc.). Furthermore, there is
a risk of complications, like deformations (capsule fibrosis of
breast implants), chronic pain, and dyspareunia, especially in
a sensitive genital region. Seconds after the implantation, the
biomaterials are covered by protein layer and 4–8 hours later
the macrophages appear and in a few days a granuloma with
fibrotic tissue appears [20]. Albumin, fibrinogen (Fg), and
immune complexes, in particular IgG, can be found onmany
surfaces after implantation, such as polyethylene terephtha-
late (PET), expanded polytetrafluoroethylene (ePTFE), poly-
dimethylsiloxane, polyurethane, and polyethylene polymers,
which are all important materials in the manufacture of the
implant [7]. Fibrin or fibrinogen modulation by the proteins
in the inflammatory response after implantation of foreign
materials in the body is particularly important. Studies show
that plasma-coated surfaces accumulate significantly less
inflammatory cells compared to uncoated surfaces [21, 22].
The profound understanding of the FBR plays the crucial role
for optimisation of biocompatibility of alloplasticmaterials in
order to reduce the complications.
An ideal graftmaterial is supposed to be chemically inert,
nontoxic, nonallergic, noninflammatory, resistant to infec-
tion, noncarcinogenic, solid, sterilizable, convenient, and
affordable [8]. New developments in material optimization
are currently tested. There are only a few groups who have
investigated polypropylene mesh modifications by surface
coating with collagen, titanium, or absorbable polymers in
animal and in vitro studies [11, 12, 23, 24].While some of these
studies found higher biocompatibility (e.g., light polypropy-
lene mesh) compared to the standard polypropylene control
group, others found very similar outcomes between the two
groups. Some of thesemeshes have been now introduced into
the market as they were thought to be associated with lower
complications [25]. Our study group was the first one to
analyse themeshmodification according to IDEAL criteria of
surgical innovation [13]. On the basis of the results presented
in this study we are currently initiating a prospective ran-
domised clinical trial for the optimization of implants in
mesh surgery. We will compare the group of native meshes
versus coated meshes for postoperative complications and
functional results. The last step of IDEAL model with long-
term surveillance of mesh grafts was successfully introduced
for hernia surgery by national and European registries [26,
27]. A consecutive urogynecological registry for implants is
currently under construction (unpublished data).
It is crucial that randomised controlled clinical trials
should be supported in the future, in particular with regard
to fundraising or industrial sponsoring. Therefore research
funders need to recognise the nature of surgical innovation to
encourage high-quality research approaches.
In the study presented here we could first transfer the
previous in vitro and animal model findings on optimisation
of mesh properties in human.The results of this research and
the developed evaluation approach formeshes could getmore
important in the future evaluating processes as the method
can be performed independent from manufacturers con-
cerns, in particular after market entry [14].
6. Conclusion
Coating of meshes with autologous plasma prior to implan-
tation is a safe procedure with no increased perioperative
complications. The modification is implemented according
to IDEAL criteria of surgical innovations (Exploration stage).
A randomized single-blinded clinical trial proving a positive
effect of plasma coating on the biocompatibility of meshes
and morbidity outcome is justified and is in the progress of
preparation (Assessment stage). A long-term surveillance of
new mesh materials will be performed in national and Euro-
pean urogynecological registries (unpublished data, EuraHS)
(Long-Term stage). In reaction to FDA reports on mesh
associated problems, our international collaboration group
presents a unique implementation of all five steps of surgical
innovations for mesh graft development in urogynecology.
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